about
Clozapine augmentation for treatment-resistant schizoaffective disorderLithium for schizophreniaMood stabilisers for schizoaffective disorderTherapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorderCREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithiumLithium facilitates apoptotic signaling induced by activation of the Fas death domain-containing receptorA novel mass spectrometry-based assay for GSK-3beta activity.Lithium in the treatment of bipolar disorder: pharmacology and pharmacogeneticsMood stabilizers, glycogen synthase kinase-3beta and cell survivalEfficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot studyLight and electron microscopy study of glycogen synthase kinase-3beta in the mouse brainAltered regulation of Akt signaling with murine cerebral malaria, effects on long-term neuro-cognitive function, restoration with lithium treatmentLithium ions Up-regulate mRNAs encoding dense-core vesicle proteins in nerve growth factor-differentiated PC12 cellsChronic lithium downregulates cyclooxygenase-2 activity and prostaglandin E(2) concentration in rat brainSHANK3 overexpression causes manic-like behaviour with unique pharmacogenetic properties.Hyperactivity, startle reactivity and cell-proliferation deficits are resistant to chronic lithium treatment in adult Nr2e1(frc/frc) micePotential therapeutic interventions for fragile X syndromeGlycogen synthase kinase-3 in the etiology and treatment of mood disorders.Gene expression alterations in bipolar disorder postmortem brains.Proteomic analysis of lithium-induced gene expression in the rat hypothalamus.A systematic review of existing data on long-term lithium therapy: neuroprotective or neurotoxic?Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder.Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome.The psychopathology and treatment of bipolar disorder.Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3).Lithium ameliorates autistic-like behaviors induced by neonatal isolation in rats.Lithium ions enhance cysteine string protein gene expression in vivo and in vitro.Neuroplasticity and cellular resilience in mood disorders.Potential molecular and cellular mechanism of psychotropic drugsEvidence of reactive astrocytes but not peripheral immune system activation in a mouse model of Fragile X syndromeMolecular basis of lithium action: integration of lithium-responsive signaling and gene expression networks.Glycogen synthase kinase 3β (GSK3β) modulates antiviral activity of zinc-finger antiviral protein (ZAP).Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues.Lithium-related genetics of bipolar disorder.Examination of IMPA1 and IMPA2 genes in manic-depressive patients: association between IMPA2 promoter polymorphisms and bipolar disorder.Potential mechanisms of action of lithium in bipolar disorder. Current understanding.Lithium prevents aberrant NMDA-induced F-actin reorganization in neurons.The underlying neurobiology of bipolar disorderThe evolving role of topiramate among other mood stabilizers in the management of bipolar disorder.Lithium long-term treatment in mood disorders: clinical and genetic predictors.
P2860
Q24186084-950E7867-BC4C-490B-94CC-9843D7F06102Q24186325-6876A2B6-1CDC-4B04-963D-84A0714E4075Q24234715-E516F5AC-CCFF-473D-8F9C-154B6AE744B1Q24626017-1B8ACDB0-03DA-4F7E-8AAC-BAF2BE0FC0C7Q24680427-5D6C50C0-AD64-4D35-B7B0-E9914943775FQ24791054-FA7E0AAA-0109-4E74-BBE1-73A50506D68BQ25257396-286471C2-9BA5-491D-91F2-78896BCBCD73Q28081249-3C1F6C75-3D45-4CF6-8BE0-44D57920B90BQ28216404-4B1C6037-89CE-43CE-AE61-8347C4187117Q28248076-9DAB5A92-8E22-498B-A62E-0F08E3864D38Q28472669-AF785645-1AD5-4258-A63E-A5C1300E4F08Q28484464-2B508E87-F996-4643-B3FA-8DF0C9BCDB8CQ28570680-537542C0-37A4-4BE2-A7FF-C382EC9160EFQ28575972-99029228-0B0F-48B3-85CB-9EB970EF209EQ30438816-DBE53556-F689-4228-9D81-8F24FB4B0B9BQ30469863-092B0957-5D57-4EED-A61B-16BE15372C3EQ30473378-905770F5-F883-4A91-9F25-F794C13A6F36Q30474415-405CFB5A-BEDB-4C4B-8568-8360F84D3C90Q30536705-A9C96E43-AE56-4849-95E5-6366486FC5E6Q30891339-B6DEEAD6-6F49-46B1-870E-F05EE72275CAQ33284843-46314904-A515-4AD4-9D95-4AB0E11E3FD9Q33573983-CB838136-4596-477D-82A4-4BCD6BE979EDQ33607288-D7A70D11-1FFC-47D5-B3A1-AAEEE4881A0FQ33619910-3CA382E0-D350-4B5B-BED9-6BE069319E7FQ33636704-CEA18444-222D-4C32-B9F8-07658B07BEC9Q33810377-9E33B9B9-7CF0-49BE-9B85-5772135D5B4DQ33902553-EBA378D2-CFB3-483B-AA49-D5229D5E3126Q34111006-151AF47D-DA5E-4129-9952-5A6BD3936184Q34129880-3BB4D121-ECB6-4285-BB74-E33048F767B8Q34142731-5A3556B2-EA3D-4518-8E3A-FAFBCB0522F2Q34180376-B1EA8063-9002-4E6B-A858-68BBC48DF53DQ34238255-587AD8DC-A9BA-4F1E-A809-CAB630999271Q34279410-2D459F0F-8C4B-4BC3-BD6D-F665439BA9FEQ34281207-D5D657EA-C6E4-45CC-AE99-7C35921A9C58Q34286895-464161E8-4E38-455B-A4D0-CD466D9ECC37Q34325612-59F0BC75-4596-482E-8F7F-532A78C8C9D3Q34421875-EACEE70A-5051-47BE-B417-31EA8DA1851EQ34562614-F7003F9F-191B-4D82-A0A7-E1D11FDBA417Q34576250-05B7D47A-A7C2-47C1-8B78-8F553BD02C30Q34609171-6F75FAD8-2229-428B-8818-270DBA41B922
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մարտին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Anti-bipolar therapy: mechanism of action of lithium.
@ast
Anti-bipolar therapy: mechanism of action of lithium.
@en
type
label
Anti-bipolar therapy: mechanism of action of lithium.
@ast
Anti-bipolar therapy: mechanism of action of lithium.
@en
prefLabel
Anti-bipolar therapy: mechanism of action of lithium.
@ast
Anti-bipolar therapy: mechanism of action of lithium.
@en
P356
P1433
P1476
Anti-bipolar therapy: mechanism of action of lithium.
@en
P2093
P2888
P304
P356
10.1038/SJ.MP.4000494
P407
P577
1999-03-01T00:00:00Z
P5875
P6179
1024877376